A retrospective, study of prescribing for erectile dysfunction in a UK population during 1997-2000: Demand was neither excessive nor continuing to rise

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 8, 2004, Pages 557-562

  Sullivan, Frank ^a   Donnelly, Louise ^a   Donnan, Peter ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Drug utilisation; Erectile dysfunction; Prescribing; Primary care

Indexed keywords

PAPAVERINE; PROSTAGLANDIN E1; PROSTAVASIN; SILDENAFIL; YOHIMBINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG EFFICACY; ERECTILE DYSFUNCTION; GENERAL PRACTICE; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NATIONAL HEALTH SERVICE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATECTOMY; REGISTER; RETROSPECTIVE STUDY; SOCIOECONOMICS; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; COMORBIDITY; DRUG UTILIZATION; GREAT BRITAIN; HUMANS; IMPOTENCE; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PIPERAZINES; RETROSPECTIVE STUDIES; VASODILATOR AGENTS;

EID: 4544278711     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.905     Document Type: Article

References (27)

1. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. Br Med J 2002; 324: 886-890.
2. NHS Executive. Treatment for impotence. Department of Health: London, 1999 (HSC 1999/148).
3. Mitchell P. UK government restricts the use of sildenafil. Lancet 1999; 353: 1687.
4. Wagner G, Seanz de Tejada I. Update on male erectile dysfunction. Br Med J 1998; 316: 678-682.
5. Morgentaler A. Male impotence. Lancet 1999; 13(354): 1713-1718.
6. Laumann EO, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 28: 537-544.
7. Read S, King M, Watson J. Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner. J Public Health Med 1997; 19: 387-391.
8. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999; 161: 5-11.
9. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-1547.
10. Kleinman KP, Feldman HA, Johannes CB, Derby CA, McKinlay JB. A new surrogate variable for erectile dysfunction status in the Massachusetts male aging study. J Clin Epidemiol 2000; 53: 71-78.
11. Teloken C, Rhoden EL, Sogari P, Dambros M, Souto CA. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998; 159: 122-124.
12. Burls A, Gold L, Clark W. Systematic review of RCTs of sildenafil in the treatment of male ED. Br J Gen Pract 2001; 51: 1004-1012.
13. Henney JE, Shuren JE, Nightingale SL, McGinnis TJ. Internet purchase of prescription drugs: buyer beware. Ann Intern Med 1999; 131: 861-862.
14. Ashworth A, Golding S, Shephard L, Majeed A. Prescribing incentive schemes in two NHS regions: cross sectional survey. Br Med J 2002; 324: 1187-1188.
15. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-462.
16. Evans JMM, McDevitt DG, MacDonald TM. The Tayside medicines monitoring unit (MEMO): a record-linkage system for pharmacovigilance. Pharmaceut Med 1995; 9: 177-184.
17. Morris AD, Boyle DIR, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet 1997; 350: 1505-1510.
18. Information and Statistics Division. ISD Scotland Guide: an A-Z of the work of the Information & Statistics Division. Edinburgh: Information & Statistics Division, 1996.
19. Carstairs V. Deprivation and health in Scotland. Health Bull (Edin) 1990; 48: 162-175.
20. Caldicott Committee. Report on the review of patient-identifiable information. London: Department of Health, 1997. www.doh.gov.uk/nhsexipu/resource/caldico/index.htm.
21. CLAM Cleaning and Anonymisation by Mapping. Described in Protecting Patient Confidentiality, available at http://www.nhsis.co.uk/csags.
22. Thomson P, MacDonald T, Sullivan F. CLAM: cleaning and anonymisation by mapping. ISPE Conference Proceedings, 2002.
23. Wilson EC, McKeen ES, Scuffham PA, Brown MC, Wylie K, Hackett G. The cost to the United Kingdom national health service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Pharmacoeconomics 2002; 20: 879-889.
24. Dunn KM, Croft PR, Hackett GI. Sexual problems: a study of the prevalence and need for health care in the general population. Fam Pract 1998; 15: 519-524.
25. Siegel RL, Glasser DB. Cost-effectiveness of sildenafil. Ann Intern Med 2001; 134: 250-251.
26. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (viagra) in the treatment of erectile dysfunction. Int J Impotence Res 1998; 10: 69-74.
27. Shakir SA, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001; 17(322): 651-652.